Descrizione Clinica
Dropyal Eye Drops 20monodosis 0,65ml Bruschettini
DROPYAL 0.015% COLLIRIES, DEAL
active ingredients
100 ml contain: Active Ingredient: hyaluronic acid salt sodium g 0.015 For excipients see paragraph 6.1.Excellent
Carbossipolymethylene; glycerol, distilled water.Therapeutic indications
Eye syndromes from the dry eye. Hydrating and lubricant of cornea and conjunctiva. Valid aid in use of contact lenses.Contraindications
Hypersensitivity to the active ingredient or any of the excipients listed in paragraph 6.1.Population
Population 1–2 drops four times or more/die, according to the doctor's opinion. Method of administration Open a sterile monodose microflaconcino by turning the upper segment of the sterile microflaconcino, istillate in the lower joint furnace the number of drops according to the indicated dosage. After opening and after the first distillation, close the bottle by pressing on the neck the capsule placed under the aletta. The residual can be used no later than 6 hours after opening, provided it is kept in a suitable environment. To avoid contamination, take care that the dropper and the microdoser capsulin do not come into contact with the eyes or with other non-sterile surfaces. Instructions for use To use the monodose microflaconcino, do the following: 1) Cut a bottle from the strip 2) Remove the spout to release it from the liquid. 3) Open the single-dose bottle by turning the fin and simultaneously pulling. Keep the aletta in one hand. 4) By exercising with the other hand a moderate pressure on the walls of the monodose bottle, slowly bring out the medicine in the prescribed dose.Conservation
Store at temperature not exceeding 30°C.Warnings
In order to avoid contamination, the microflaconcino and the capsulin, once separated, should not enter into direct contact with the eyes or other surfaces.Interactions
Interactions with other systemic or topical drugs have never been reported.Effects
In rare cases, slightly transitory burning to the distillation. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions occurring after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction through the national reporting system www.agenziafarmaco.gov.it/it/responsabili.Overdosing
Overdose cases have never been reported.No known contraindications.
Source: Farmadati
